100¦~10¤ë¸¹ ¹D ªk ªk °T (235)

DEEP & FAR

 

 

²£«~»sµ{½Ð¨D¶µ¤§¸ÑŪ¤è¦¡(¤@)

(Fed. Cir.2007-1400)

 

³¯ºaºÖ ±M§Q¥N²z¤H

¡E¤¤°êÂåÃľǰ|ÃľǨt¾Ç¤h

¡E¤é¥»ºÖ©£¤j¾Ç¥ÍÃľǩҺӤh

¡E¶§©ú¤j¾ÇÂå¾ÇÃIJz©Ò³Õ¤h

 

 

¥»®×«Y¥H¬Û¦P¤§¬ü°ê±M§Q²Ä4,935,507¸¹¡]²¤ºÙ¡¦507 ±M§Q¡^([1])¡A©ó¬ü°êºû¦N¥§¨È¦{ªF°Ï¦a¤èªk°|©M¥ì§Q¿Õ¦{¥_°Ï¦a¤èªk°|¤§¨â¦aµo¥Í¶D³^¡Cºû¦N¥§¨È¦{ªF°Ï¦a¤èªk°|­ã¤©Lupin ¤½¥q©MLupinÃÄ«~¤½¥q (¦XºÙLupin)¡AµL«IÅv¤§Â²©ö§P¨MÁn½Ð¡C¥t¤@®×¥ó©ó¥ì§Q¿Õ´µ¦{¦a¤èªk°|¡A°ò©óºû¦N¥§¨È¦{ªF°Ï¦a¤èªk°|¤§¥Ó½Ð±M§Q½d³ò¸ÑÄÀ¡A¹ï©ó»é¦^¡¦507 ±M§Q±MÄݳQ±ÂÅv¤H¤§Abbott»sÃÄ(Abbott Laboratories) µo¥X»é¦^ªì¨B¸T¨î¥O¡C

 

¦]¬°ºû¦N¥§¨È¦{ªF°Ï¦a¤èªk°|¥¿½T¦a¸ÑÄÀ¡¦507 ±M§Q¤§½Ð¨D¶µ½d³ò¡A¥B¥¿½T¦a¹îı¹ï±M§Q½d³ò 2-5¤§¦r­±«IÅvµL­«­n¨Æ¹ê¤W¤§¯u¥¿ª§Ä³¦s¦b¡A¥çµL³z¹L½Ð¨D¶µ1-5¶µ§¡µ¥ª«¤§«IÅv¦æ¬°¡A¬Gªk°|©ó³¡¤À²©ö§P¨M½T»{©wµL«IÅv¡C¦P®É¡A¸Óªk°|ªÖ©w¥ì§Q¿Õ¦{¥_°Ï¦a¤èªk°|¡A°ò©ó¤j³¡¥÷¤W¬Û¦P¤§¥¿½T¥Ó½Ð±M§Q½d³ò¸ÑÄÀ¡A¦Ó»é¦^Abbott¹ïªì¨B¸T¨î¥O¤§½Ð¨D¡C

I.

¡¦507 ±M§Q¤§±MÄݳQ±ÂÅv¤H¡AAbbott»sÃÄ¡A®Ú¾Ú¡¦507 ±M§Q¥H°Ó¼Ð¦WºÙ ¡§Omnicef¡¨¾P°â´¹ÅéÀYÌU¦a¥§ (cefdinir)¡Cºû¦N¥§¨È®×µo¥Í©óLupin°w¹ï¡¦507 ±M§Q¤§©Ò¦³ªÌAbbott»sÃÄ»PAstellas ÂåÃĤ½¥q(²ÎºÙAbbott) ´M¨DµL«IÅv½T»{¤§§P¨M¡C¬ü°ê­¹«~¤ÎÃÄ«~ºÞ²z§½¥ý«e¤w§å­ãLupin¤§Â²¤Æ·sÃĥӽР(ANDA)¡A¥i³c°âOmnicef ¤§¾Ç¦WÃÄ¡CLupin¾Ç¦WÃIJ£«~¡A´X¥G±Mªù¥]§tÀYÌU¦a¥§µ²´¹B ¤§´¹«¬(ÀYÌU¦a¥§³æ¤ô¦Xª«, cefdinir monohydrate)¡A¦ÓAbbott»sÃĤ§Omnicef ²£«~«h«Y¥]§tµÛÀYÌU¦a¥§µ²´¹A¤§ÀYÌU¦a¥§µL¤ô¦Xª« (cefdinir anhydrate) ´¹«¬¡C

 

  



[1]. ±M§Q¦WºÙCrystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3- vinyl-3-cephem-4-carboxylic acid (syn isomer), August 8, 1988¥Ó½Ð,Åý»PFujisawa Pharmaceutical Co., Ltd.